[1]CurrentPatentAssignee:BUKWANGPHARMACEUTICALCO.,LTD.-WO2019/139185,2019,A1Locationinpatent:Paragraph78-89
[2]Lipinski,C.A.;Stam,J.G.;Pereira,J.N.;Ackerman,N.R.;Hess,H.-J.[JournalofMedicinalChemistry,1980,vol.23,#9,p.1026-1031]
[1]Lipinski,C.A.;Stam,J.G.;Pereira,J.N.;Ackerman,N.R.;Hess,H.-J.[JournalofMedicinalChemistry,1980,vol.23,#9,p.1026-1031]
[1]Lipinski,C.A.;Stam,J.G.;Pereira,J.N.;Ackerman,N.R.;Hess,H.-J.[JournalofMedicinalChemistry,1980,vol.23,#9,p.1026-1031]
[1]CurrentPatentAssignee:BUKWANGPHARMACEUTICALCO.,LTD.-KR101827744,2018,B1
[2]CurrentPatentAssignee:BUKWANGPHARMACEUTICALCO.,LTD.-WO2019/139185,2019,A1
Title: The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Journal: The Journal of pharmacology and experimental therapeutics 20120701
Title: MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Journal: The Journal of pharmacology and experimental therapeutics 20120701
Title: Saporito MS, et al. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J Pharmacol Exp Ther. 2012 Jul;342(1):15-22.
Title: Ochman AR, et al. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J Pharmacol Exp Ther. 2012 Jul;342(1):23-32.
